Skip to main content
TipRanks
Go Ultimate75% OFF

Arbutus Biopharma (0SGC) Share Price & Analysis

1 Followers

0SGC Stock Chart & Stats

$3.32$0.00(0.00%)
At close: 4:30 PM GMT
$3.25$3.5$3.75Nov 4Nov 19Dec 2Dec 16Dec 30Jan 13Jan 27
Day’s Range
$3.32 - $3.32
52-Week Range
$3.32 - $3.32
Previous Close
$3.32
Volume
N/A
Average Volume (3M)
0
Market Cap
$619.30M
Enterprise Value
$620.04M
Total Cash (Recent Filing)
$337.49M
Total Debt (Recent Filing)
$328.00K
Price to Earnings (P/E)
3.6
Beta
1.25
Next Earnings
Mar 04, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Profitability And Cash Generation

The latest period shows a substantial shift to profitability, with very high margins and strong operating and free cash flow. If this improvement persists, it could provide substantial internal funding for clinical development, reduce financing dependence, and strengthen strategic flexibility over the next several quarters.

Low Financial Leverage

Minimal debt gives Arbutus considerable financial flexibility relative to a more heavily leveraged biotechnology company. The balance sheet can support continued research investment and help the company withstand development uncertainty without the same interest burden or refinancing pressure associated with substantial borrowing.

HBV Pipeline Progress

The reported clinical activity strengthens the strategic case for Arbutus’s HBV platform, particularly because current treatment options are often lifelong and non-curative. Durable suppression and functional cure signals could support further development, partnering interest, and differentiation if confirmed in later studies.

Bears Say

Declining And Volatile Revenue

A falling latest-period revenue base makes the current earnings step-change harder to assess as a durable operating trend. Volatile revenue can complicate planning and reduce confidence in recurring funding capacity, especially while the company continues advancing clinical programs that require sustained investment.

Inconsistent Cash Flow History

The contrast between recent cash generation and several years of cash burn indicates that the latest result has not yet established a reliable pattern. If historical volatility returns, Arbutus may need to conserve resources, raise external capital, or reduce development flexibility to fund its pipeline.

Limited Recurring Product Revenue

Arbutus does not yet have a broadly commercialized product base producing recurring operating revenue, leaving financial performance dependent on collaborations, licensing payments, investment income, and external financing. This increases the importance of successful development and commercialization milestones for long-term self-funding.

Arbutus Biopharma News

0SGC FAQ

What was Arbutus Biopharma’s price range in the past 12 months?
Arbutus Biopharma lowest share price was $3.32 and its highest was $3.32 in the past 12 months.
What is Arbutus Biopharma’s market cap?
Arbutus Biopharma’s market cap is $619.30M.
When is Arbutus Biopharma’s upcoming earnings report date?
Arbutus Biopharma’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 107 days.
How were Arbutus Biopharma’s earnings last quarter?
Arbutus Biopharma released its earnings results on Nov 10, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of -$0.023 by $0.323.
Is Arbutus Biopharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Arbutus Biopharma pay dividends?
Arbutus Biopharma does not currently pay dividends.
What is Arbutus Biopharma’s EPS estimate?
Arbutus Biopharma’s EPS estimate is -0.02.
How many shares outstanding does Arbutus Biopharma have?
Arbutus Biopharma has 153,292,830 shares outstanding.
What happened to Arbutus Biopharma’s price movement after its last earnings report?
Arbutus Biopharma reported an EPS of $0.3 in its last earnings report, beating expectations of -$0.023. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Arbutus Biopharma?
Hedge funds hold Arbutus Biopharma shares: the largest hedge-fund position in Arbutus Biopharma is 19,977,581 shares, and hedge funds decreased their holdings by 476.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology